background
search
diseas
biomark
within
human
peripher
fluid
becom
favor
approach
prevent
therapeut
throughout
past
year
comparison
normal
versu
diseas
state
identifi
overexpress
suppress
critic
protein
ill
directli
alter
patient
cellular
homeostasi
particular
analysi
infect
serum
attract
medium
identifi
alter
protein
express
due
eas
noninvas
method
collect
sampl
well
correspond
insight
vivo
interact
viru
infect
cellstissu
util
proteom
techniqu
global
identifi
differenti
express
serum
protein
respons
infect
signific
undertak
complic
due
innat
protein
profil
human
serum
deplet
abund
serum
protein
follow
twodimension
gel
electrophoresi
coupl
identif
protein
use
matrixassist
laser
desorptionion
timeofflight
malditof
mass
spectrometri
allow
identif
differenti
express
low
abund
serum
protein
analyz
compar
serum
sampl
infect
subject
treat
use
highli
activ
antiretrovir
therapi
haart
latent
infect
progress
aid
despit
absenc
treatment
ie
long
term
nonprogressor
ltnp
identifi
uniqu
serum
protein
differenti
express
ltnp
patient
may
contribut
abil
patient
combat
infect
absenc
haart
focus
cell
cycl
inhibitor
found
treatment
latent
infect
cell
line
decreas
viral
product
despit
express
endogen
cell
identif
uniqu
protein
may
serv
indic
alter
viral
state
respons
infect
well
natur
phenotyp
variabl
respons
infect
given
popul
human
serum
deriv
liquid
plasma
compon
blood
fibrinogen
clot
factor
remov
compos
small
molecul
salt
lipid
amino
acid
sugar
approxim
mg
proteinsml
serum
readili
obtain
peripher
bodili
fluid
protein
profil
directli
reflect
normal
diseas
state
organ
serum
complex
mixtur
classic
nonclass
protein
classic
serum
protein
involv
number
process
includ
proteolysi
inhibit
bind
transport
coagul
immun
respons
often
secret
liver
intestin
bloodstream
nonclass
protein
protein
directli
tie
known
function
within
serum
often
origin
cellular
leakag
shed
may
util
bloodstream
transport
gener
accept
signific
chang
serum
found
low
abund
nonclass
protein
due
hypothesi
presenc
protein
reflect
chang
diseas
tissu
inde
serum
commonli
contain
upward
differ
protein
given
time
activ
produc
secret
cell
tissu
therefor
proteom
profil
serum
give
insight
system
reaction
diseas
state
serv
pool
differenti
express
protein
recent
interest
character
human
serum
proteom
increas
due
determin
diseas
biomark
earli
detect
diagnosi
drug
target
howev
due
extens
dynam
rang
protein
concentr
within
serum
identif
low
abund
protein
suitabl
biomark
determin
often
mask
highli
abund
protein
contain
within
serum
constitut
approxim
total
serum
protein
includ
albumin
igg
transferrin
haptoglobin
fibrinogen
etc
interfer
identif
low
abund
protein
ngml
concentr
rang
presenc
highli
abund
protein
necessit
prefraction
serum
sampl
prior
analysi
low
abund
protein
due
dynam
insight
analysi
serum
proteom
relat
diseas
state
particular
interest
identif
low
abund
protein
chang
express
abund
respons
diseas
state
low
abund
protein
could
potenti
aris
earli
diagnost
diseas
state
therapeut
target
serum
proteom
emerg
integr
biomark
identif
diagnost
tool
especi
infecti
diseas
oncolog
recent
novel
serum
biomark
identifi
liver
fibrosi
hepat
c
viru
hcv
infect
patient
well
uniqu
protein
signatur
sar
coronaviru
infect
infant
hepat
syndrom
induc
human
cytomegaloviru
hcmv
infect
character
serum
protein
profil
viral
state
help
provid
insight
express
chang
associ
viral
infect
particular
infect
even
acut
phase
result
dramat
chang
cellular
viral
protein
express
level
viral
tropism
consist
primarili
tcell
macrophag
dendrit
cell
result
protein
chang
seen
system
infect
cell
travel
throughout
bodi
addit
natur
viral
infect
support
secret
alter
protein
blood
subsequ
serum
due
propens
viru
stimul
apoptosi
infect
cell
therefor
empti
cellular
content
serum
characterist
infect
suggest
analysi
serum
infect
patient
appropri
reflect
patient
alter
protein
express
state
due
innat
genet
phenotyp
differ
human
popul
signific
variabl
exist
suscept
infect
amongst
divers
includ
wellstudi
inherit
mutat
prevent
bind
strain
chemokin
receptor
surfac
tcell
therefor
prevent
entri
viru
addit
individu
infect
howev
progress
aid
even
absenc
therapi
long
term
nonprogressor
ltnp
often
character
infect
also
diseas
free
sustain
normal
tcell
count
low
viral
load
past
year
multipl
studi
aim
determin
reason
individu
abl
resist
diseas
progress
studi
suggest
viru
infect
cell
could
defici
way
exampl
nef
defici
virus
vpr
mutat
associ
ltnp
number
host
factor
also
identifi
may
contribut
observ
resist
ltnp
higher
preval
allel
addit
presenc
certain
hla
gene
includ
hlab
hlab
hlab
link
ltnp
howev
identifi
alter
account
case
ltnp
therefor
search
protect
host
factor
still
area
activ
investig
hope
obtain
inform
could
therapeut
valu
describ
detect
uniqu
low
abund
serum
protein
latent
infect
ltnp
compar
serum
patient
undergo
haart
treatment
infect
attempt
character
underli
differ
ltnp
contribut
abil
patient
combat
infect
deplet
highli
abund
serum
protein
three
set
serum
sampl
uninfect
infect
haart
ltnp
identifi
differenti
express
protein
across
sampl
particular
focu
identifi
cellular
protein
found
preferenti
ltnp
patient
serum
sampl
present
patient
undergo
haart
treatment
vitro
viral
assay
viabil
studi
confirm
loss
viral
replic
upon
treatment
latent
infect
cell
line
nontox
effect
treatment
correspond
uninfect
cell
line
begin
identif
uniqu
serum
protein
obtain
subject
serum
sampl
six
ltnp
six
infect
subject
receiv
haart
therapi
haart
six
hivuninfect
individu
washington
dc
site
women
interag
hiv
studi
wih
georgetown
site
tabl
wih
nih
multicent
studi
natur
histori
infect
women
ltnp
defin
wih
infect
diseas
free
least
five
year
count
greater
visit
histori
antiretrovir
therapi
difficulti
associ
analyz
serum
presenc
high
abund
protein
mask
potenti
low
abund
biomark
overcom
obstacl
util
proteomelab
igi
serum
deplet
kit
remov
abund
protein
serum
albumin
igg
transferrin
fibrinogen
iga
igm
haptoglobin
glycoprotein
apolipoprotein
ai
apolipoprotein
aii
observ
figur
whole
serum
lane
contain
mani
protein
complex
allow
confid
identif
specif
protein
howev
high
abund
protein
figur
lane
remov
lower
abund
protein
origin
mask
figur
lane
abl
analyz
along
line
found
proteomelab
igi
serum
deplet
kit
appropri
reproduc
manner
fraction
serum
sampl
high
low
abund
fraction
appli
deplet
strategi
pool
patient
sampl
combin
equal
volum
whole
serum
six
patient
per
sampl
set
ltnp
haart
neg
subsequ
deplet
low
high
abund
fraction
began
analysi
pool
sampl
assist
identif
infect
specif
protein
identif
oppos
identifi
individu
patient
serum
variabl
pool
sampl
separ
base
sdspage
figur
comparison
ltnp
haart
neg
low
abund
sampl
carri
via
ingel
trypsin
digest
peptid
elut
desalt
follow
malditof
mass
spectrometri
indic
number
arrow
mark
excis
band
subsequ
protein
identif
serv
preliminari
indic
differenti
express
protein
three
patient
type
observ
summar
tabl
provid
insight
relev
protein
identifi
context
state
infect
particular
interest
tabl
identif
enhanc
bind
protein
ribonucleas
iii
heterochromatin
protein
bind
protein
low
abund
ltnp
fraction
member
za
famili
protein
bind
promot
enhanc
region
cellular
gene
infecti
virus
includ
also
known
transcript
factor
bind
tar
transactiv
respons
dna
element
ltr
presenc
absenc
tat
surpris
transcript
factor
would
present
infect
howev
identif
protein
necessarili
marker
ltnp
phenotyp
ribonucleas
iii
drosha
cellular
enzym
found
nucleu
serv
cleav
doublestrand
rna
hairpin
transcript
key
step
product
mirna
rna
interfer
pathway
interestingli
heterochromatin
protein
member
chromatin
remodel
famili
protein
bind
histon
methyl
lysin
residu
interact
mani
chromatinassoci
nonhiston
protein
famili
protein
associ
promot
heterochromat
cellular
state
latent
infect
cell
persist
transcript
silent
proviru
may
interest
bind
protein
would
present
serum
infect
patient
includ
subtyp
could
involv
control
variou
stage
infect
possibl
associ
bind
protein
vari
subtyp
could
explain
differ
patient
phenotyp
especi
result
alter
suscept
viral
infect
follow
initi
separ
malditof
ms
assist
identif
pool
patient
sampl
subject
electrophoresi
isoelectr
focus
ief
use
ipg
strip
ph
rang
follow
sdspage
use
trisglycin
criterion
gel
method
electrophoresi
much
sensit
electrophoresi
provid
separ
complex
mixtur
protein
two
dimens
therefor
remov
complex
associ
overlap
protein
mask
due
posttransl
modif
sensit
frontend
purif
approach
isol
identif
individu
protein
speci
mass
spectrometri
figur
depict
ltnp
haart
neg
low
abund
fraction
gel
b
c
respect
well
ltnp
haart
neg
high
abund
fraction
gel
e
f
respect
indic
protein
spot
gel
excis
base
comparison
protein
abund
presenc
uniqu
spot
given
patient
set
subject
ingel
trypsin
digest
identifi
malditof
mass
spectrometri
import
note
although
gel
e
f
contain
major
high
abund
protein
uniqu
small
protein
spot
still
visual
gel
indic
high
abund
protein
mask
protein
interest
also
interact
seclud
lower
abund
protein
identifi
peak
list
collect
mass
spectra
process
via
peptid
mass
fingerprint
pmf
analysi
use
mascot
profound
databas
compar
compil
nonexhaust
list
identifi
protein
display
tabl
particular
interest
protein
identifi
gel
indic
uniqu
low
abund
protein
serum
ltnp
patient
tropomyosin
protein
kinas
bind
protein
tropomyosin
interact
actin
filament
provid
stabil
regul
actin
bind
protein
famili
protein
shown
cleav
proteas
vitro
result
dissoci
critic
cytoskelet
element
may
demonstr
alter
muscl
structur
presenc
infect
protein
kinas
protein
kinas
c
pkc
member
famili
serinethreonin
kinas
integr
involv
key
cellular
signal
pathway
phosphoryl
wide
varieti
substrat
surprisingli
infect
alter
pkc
phosphoryl
pathway
stimul
product
monocyt
well
cytokin
growth
factor
pkc
also
shown
necessari
tatmedi
transactiv
well
directli
phosphoryl
tat
serin
play
integr
role
signal
secret
cytokin
respons
envelop
protein
particular
interest
low
abund
ltnp
fraction
presenc
bind
protein
specif
member
inhibitor
kinas
read
frame
famili
endogen
cdk
cyclindepend
kinas
inhibitor
dysregul
cell
cycl
includ
manipul
cdk
associ
cyclin
often
hallmark
cancer
infecti
phenotyp
inde
associ
protein
known
alter
phosphoryl
state
activ
kinas
inhibit
phosphoryl
rb
competit
inhibit
associ
therefor
inhibit
releas
rbbound
protein
subsequ
progress
phase
cell
cycl
small
molecular
weight
protein
attract
candid
secret
differenti
express
protein
respons
infect
addit
low
abund
protein
identif
ltnp
high
abund
sampl
gel
indic
presenc
oncogen
partner
pctair
protein
kinas
well
igg
light
chain
oncogen
partner
fibroblast
growth
factor
receptor
thought
associ
myeloprolif
disord
yet
associ
protein
interact
associ
diseas
phenotyp
pctair
protein
kinas
howev
member
serinethreonin
famili
protein
kinas
specif
subfamili
play
role
broad
signal
transduct
pathway
serinethreonin
kinas
famili
member
also
associ
essenti
regul
cell
cycl
progress
well
transcript
dna
repair
protein
identif
demonstr
role
infect
play
dysregul
cellular
kinas
specif
cell
cycl
progress
haart
respond
patient
sampl
gel
b
e
also
contain
uniqu
protein
candid
serin
threonin
kinas
kelch
repeat
domain
contain
protein
interact
protein
low
abund
fraction
well
prebcel
leukemia
homeobox
interact
protein
high
abund
fraction
function
interest
gener
serinethreonin
kinas
alreadi
identifi
sever
cellular
kinas
famili
addit
protein
transcript
coactiv
induc
express
vitamin
retino
acid
estrogen
glucocorticoid
associ
gene
interact
tat
associ
ptefb
tar
rna
complex
stimul
transcript
elong
interestingli
protein
spot
identifi
presenc
serum
albumin
contamin
spot
serv
intern
posit
control
mass
spectrometri
also
indic
deplet
column
complet
effici
remov
contamin
high
abund
protein
order
confirm
presenc
protein
serum
identifi
mass
spectrometri
perform
western
blot
low
high
abund
pool
fraction
figur
present
low
high
abund
fraction
pool
ltnp
lane
also
observ
high
abund
fraction
uninfect
patient
figur
lane
interestingli
protein
present
haart
patient
sampl
figur
lane
presenc
protein
serum
may
specif
individu
confer
resist
chronic
infect
inhibitor
cell
cycl
kinas
particular
level
serum
sampl
assay
shown
ubiquit
express
across
low
high
abund
serum
sampl
figur
third
panel
top
inde
level
detect
patient
serum
sampl
compar
whole
cell
extract
posit
control
data
shown
impli
presenc
serum
depend
presenc
absenc
likewis
affect
express
level
amongst
patient
serum
sampl
bind
protein
initi
identifi
spectrometri
analysi
ltnp
low
abund
fraction
therefor
serum
level
subunit
assay
figur
famili
heterochromatinassoci
protein
exist
three
distinct
isoform
act
regul
heterochromatinmedi
transcript
silenc
shown
directli
interact
dna
methyltransferas
histon
methyltransferas
mediat
transcript
silenc
particular
interact
histon
methyltransferas
initi
chromatinmedi
repress
state
integr
viru
shown
present
low
abund
fraction
patient
phenotyp
wherea
shown
present
low
high
abund
fraction
across
patient
type
figur
observ
lower
amount
neg
haart
high
abund
fraction
serum
sampl
indic
presenc
posttransl
modif
ie
doublet
band
compar
whole
cell
extract
posit
control
indic
found
serum
exist
modifi
unmodifi
form
interestingli
pctair
present
highest
abund
uninfect
neg
high
abund
fraction
figur
lane
howev
low
level
also
seen
ltnp
haart
high
abund
fraction
figur
lane
pctair
identifi
initi
mass
spectrometri
high
abund
ltnp
sampl
seen
high
abund
fraction
three
patient
type
biochem
howev
present
lower
amount
infect
patient
indic
kinas
may
differenti
express
upon
infect
though
necessarili
uniqu
identifi
infect
protein
identifi
mass
spectrometr
analysi
confirm
biochem
specif
collect
flowthrough
column
wash
lane
high
abund
protein
elut
lane
briefli
observ
high
abund
protein
compar
known
size
expect
protein
indic
b
equal
volum
serum
six
patient
within
categori
ltnp
haart
neg
pool
togeth
creat
stock
condit
independ
patienttopati
variabl
twenti
microlit
stock
subject
deplet
equal
concentr
low
high
fraction
run
gel
lane
low
abund
fraction
pool
ltnp
haart
neg
patient
respect
lane
high
abund
fraction
pool
ltnp
haart
neg
patient
respect
indic
arrow
repres
differenti
express
protein
excis
trypsin
identifi
use
malditof
preliminari
protein
screen
low
abund
ltnp
serum
sampl
although
protein
also
identifi
uninfect
high
abund
ltnp
fraction
result
also
interest
due
involv
alter
cell
cycl
control
addit
mutat
found
variou
cancer
includ
pancreat
lymphoma
sarcoma
contribut
cancer
progress
find
also
indic
differ
composit
serum
protein
present
infect
individu
undergo
haart
treatment
versu
natur
nonprogress
order
address
concern
protein
signatur
pool
set
sampl
patient
type
may
accur
represent
individu
variabl
could
present
screen
low
abund
fraction
ltnp
presenc
result
figur
indic
lack
detect
low
abund
ltnp
sampl
especi
compar
pool
sampl
lane
contrast
detect
ltnp
patient
well
pool
sampl
correspond
high
abund
fraction
lane
due
natur
deplet
step
base
immunoaffin
surpris
detect
individu
high
abund
sampl
probabl
coupl
larger
abund
protein
effici
deplet
addit
postdeplet
low
abund
fraction
patient
dilut
protein
level
undetect
tradit
method
detect
ltnp
low
abund
individu
sampl
variabl
abund
correl
data
figur
interestingli
detect
ltnp
high
abund
individu
sampl
indic
protein
effect
isol
away
high
abund
protein
although
straight
western
blot
level
undetect
figur
indic
inde
immunoprecipit
individu
low
abund
ltnp
sampl
subsequ
detect
western
blot
lane
repres
pool
sampl
patient
sampl
respect
pool
sampl
incub
patient
sampl
incub
three
immunoprecipit
subject
stringent
wash
condit
tne
tne
tne
order
remov
nonspecif
protein
seen
figur
although
identifi
differenti
present
serum
infect
ltnp
compar
haart
treat
individu
may
directli
correl
viral
pathogenesi
function
protein
order
gain
insight
reason
may
present
preferenti
serum
ltnp
patient
treat
latent
infect
cell
line
exogen
purifi
figur
depict
rt
assay
measur
viral
revers
transcriptas
activ
infect
cell
indic
function
particl
product
presenc
ug
latent
infect
tcell
exhibit
decreas
rt
activ
cpm
wherea
higher
concentr
abl
elicit
decreas
rt
activ
latent
infect
monocyt
compar
gst
treatment
alon
data
suggest
presenc
serum
may
result
decreas
viral
replic
may
help
explain
presenc
serum
ltnp
could
correl
overal
lack
viral
activ
detect
whether
effect
normal
uninfect
cell
perform
mtt
assay
screen
percentag
cell
viabl
treatment
figur
depict
cem
jurkat
uninfect
tcell
line
well
uninfect
monocyt
cell
line
treat
gst
well
cem
control
cell
show
appreci
decreas
cellular
viabil
upon
hour
treatment
four
condit
interestingli
presenc
ug
jurkat
cell
exhibit
almost
decreas
cellular
viabil
next
perform
western
blot
whole
cell
extract
four
uninfect
cell
line
observ
jurkat
cell
exhibit
endogen
express
figur
lane
suggest
decreas
cellular
viabil
seen
jurkat
cell
figur
treat
correl
express
exogen
cell
result
increas
inhibit
increas
apoptosi
interestingli
endogen
level
detect
infect
cell
critic
member
rb
tumorsuppressor
pathway
act
arrest
cellcycl
inhibit
bind
cyclin
subsequ
inhibit
phosphoryl
rb
figur
investig
level
rb
present
jurkat
cell
alon
lane
compar
jurkat
cell
treat
excess
gst
lane
interestingli
upon
treatment
exogen
observ
decreas
cellular
level
rb
inde
also
decreas
rb
gst
treatment
alon
rb
antibodi
use
detect
total
rb
level
cell
therefor
could
assum
loss
phosphoryl
due
inhibitori
effect
recent
paper
address
literaturewid
discrep
rb
dephosphoryl
vs
degrad
respons
drug
treatment
cell
senesc
variou
cell
type
possibl
increas
amount
present
cell
induc
proteasom
degrad
rb
otherwis
character
cell
cell
line
panel
figur
also
screen
presenc
endogen
level
rb
cell
line
interestingli
high
degre
variabl
cell
line
cem
jurkat
infect
highest
endogen
level
rb
interestingli
monocyt
cell
line
infect
lowest
amount
rb
present
almost
complet
undetect
level
infect
cell
variabl
support
discrep
seen
literatur
hypo
hyperphosphoryl
rb
well
deplet
degrad
rb
cell
cycl
cellular
respons
order
confirm
effect
seen
gst
treatment
figur
b
c
check
ensur
purifi
protein
actual
enter
cell
jurkat
cell
line
treat
excess
gst
figur
hour
post
treatment
cell
harvest
wash
extens
lyse
incub
glutathionesepharos
bead
overnight
glutathionesepharos
bead
wash
extens
remov
nonspecif
protein
buffer
contain
salt
deterg
bound
protein
subject
western
blot
presenc
shown
figur
jurkat
whole
cell
extract
serv
posit
control
blot
higher
molecular
weight
band
correspond
observ
pulldown
lane
cell
line
lane
blot
lack
detect
untreat
cell
lysat
incub
bead
alon
indic
protein
detect
lane
specif
gstbound
protein
studi
confirm
gst
protein
inde
enter
cell
incub
extracellular
environ
order
confirm
cellular
effect
shown
figur
specif
natur
biolog
activ
inhibitor
attempt
mimic
studi
small
molecul
compound
inhibitor
fascaplysin
fascaplysin
fasc
natur
deriv
molecul
isol
marin
spong
specif
inhibit
interact
ic
approxim
lesser
extent
bind
atp
pocket
result
cell
cycl
arrest
treat
latent
infect
cell
line
three
concentr
fasc
nm
nm
collect
supernat
hour
post
treatment
rt
activ
cell
presenc
fasc
decreas
time
increas
concentr
drug
indic
presenc
gener
inhibitor
abl
correl
viabil
assay
present
figur
approxim
jurkat
cell
kill
due
addit
inhibit
fasc
treatment
none
cell
line
exhibit
appreci
cell
death
indic
drug
treatment
toxic
cell
figur
investig
level
rb
present
jurkat
cell
alon
lane
compar
jurkat
cell
treat
three
concentr
fasc
lane
correl
exogen
treatment
data
figur
observ
decreas
total
cellular
rb
level
highest
concentr
fasc
set
data
confirm
cellular
effect
observ
exogen
may
due
specif
cdk
inhibitori
activ
molecul
interest
note
effect
seen
simpl
protein
treatment
cell
purifi
molecul
may
effici
entri
compar
transfect
drug
treatment
suggest
serum
may
abl
enter
exit
lymphocyt
exhibit
inhibitori
effect
infect
previous
show
fascaplysin
treatment
result
loss
cellular
viabil
jurkat
cell
well
decreas
viral
product
infect
cell
interest
detect
cell
cycl
pattern
jurkat
respons
fascaplysin
treatment
cell
treat
three
concentr
fasc
nm
nm
collect
hour
cell
fix
stain
propidium
iodid
cell
cycl
analyz
use
facscalibur
flow
cytomet
figur
presenc
addit
inhibitor
observ
normal
arrest
effect
major
appreci
differ
cell
cycl
fasc
treat
howev
look
protein
profil
endogen
express
rb
surpris
monocyt
cell
line
would
exhibit
differ
inhibitori
pathway
taken
togeth
cell
cycl
data
shown
figur
support
overal
notion
inhibitori
effect
fascaplysin
global
proteom
analysi
serum
protein
without
challeng
howev
presenc
absenc
protein
bodili
fluid
patient
often
accur
reflect
cellular
leakag
secret
protein
respons
diseas
state
unfortun
classic
serum
proteom
contain
larg
concentr
high
abund
protein
mask
individu
protein
uniqu
particular
phenotyp
identif
low
abund
serum
protein
attract
method
earli
detect
diseas
state
respons
infect
demonstr
detect
uniqu
protein
serum
infect
longterm
nonprogressor
may
indic
natur
immun
progress
infect
specif
identifi
inhibitor
preferenti
present
pool
serum
ltnp
patient
oppos
infect
individu
respond
haart
treatment
member
famili
endogen
cdki
serv
regul
cell
cycl
progress
inhibit
specif
cdkcyclin
interact
critic
member
tumorsuppressor
pathway
inhibit
activ
prevent
progress
cell
cycl
tumorsuppress
pathway
mutat
close
human
cancer
specif
lossoffunct
mutat
found
within
rb
gene
gene
encod
addit
direct
inactiv
two
protein
cancer
cell
also
overrid
regulatori
pathway
overexpress
cdk
cyclin
well
induc
endogen
loss
express
cdk
inhibitor
loss
result
constitut
activ
well
prb
hyperphosphoryl
therefor
bypass
antioncogen
senesc
induc
cdk
inhibitor
addit
necessit
oncogen
state
regul
manipul
cellular
cdk
cyclin
also
critic
activ
viral
infect
occur
mainli
transactiv
tat
tat
interact
e
complex
phosphoryl
assist
phosphoryl
ctermin
domain
ctd
rna
pol
ii
viral
ltr
longtermin
repeat
promot
viral
transcript
also
involv
direct
phosphoryl
tat
serin
critic
effici
tat
activ
transactiv
also
heavili
depend
recruit
complex
viral
tar
element
also
assist
phosphoryl
ctd
rna
pol
ii
well
autophosphoryl
event
import
local
nucleu
take
consider
recruit
cellular
kinas
transcript
surpris
pharmacolog
cdk
inhibitor
develop
analog
endogen
cdki
templat
specif
inhibit
kinas
therefor
presenc
cdk
inhibitor
ltnp
serum
suggest
exist
defens
mechan
patient
impart
predisposit
lack
diseas
progress
develop
pharmacolog
cdki
peptid
mimet
commonli
use
approach
cancer
viral
therapeut
instanc
peptid
previous
develop
conjug
local
proteinspeptid
abl
block
cell
cycl
progress
breast
cancer
colon
cancer
cell
line
vitro
well
reduc
tumor
size
vivo
mous
model
pancreat
cancer
peptid
also
use
intracellular
deliveri
leukemia
lymphoma
deriv
cell
studi
demonstr
abil
cdkideriv
peptid
use
direct
cell
cycl
arrest
treatment
metastat
cancer
type
therapi
appropri
approach
cancer
state
oncogen
mutat
result
loss
function
express
studi
also
chose
reinforc
cdki
effect
seen
cellular
viabil
viral
replic
known
inhibitor
fascaplysin
show
treatment
jurkat
cell
inhibitor
also
result
decreas
cellular
viabil
consist
effect
seen
treatment
endogen
addit
treatment
stabli
infect
cell
line
fascaplysin
result
decreas
viral
replic
minim
decreas
cellular
viabil
correl
pharmacolog
cdki
inhibitor
data
functionalcdki
data
suggest
preferenti
inhibit
interact
ltnp
may
contribut
phenotyp
high
low
abund
fraction
analyz
three
patient
type
pool
represent
six
individu
patient
sampl
almost
certainli
inher
variabl
inde
assay
high
low
abund
serum
fraction
individu
ltnp
patient
present
subset
patient
analyz
indic
although
may
serv
uniqu
serum
protein
indic
ltnp
infect
statu
individu
persontoperson
chang
alter
serum
proteom
profil
need
taken
consider
differ
express
due
either
host
cellular
respons
infect
influenc
infect
two
differ
scenario
need
final
mani
complic
factor
contribut
alter
state
protein
present
serum
least
length
time
patient
infect
age
gender
coinfect
preexist
condit
cancer
metabol
diseas
therefor
import
take
consider
factor
appli
global
proteom
analys
patient
deriv
sampl
endotheli
kidney
cell
line
harvest
whole
cell
extract
use
posit
control
grown
dulbecco
modifi
eagl
medium
dmem
contain
fb
lglutamin
streptomycinpenicillin
qualiti
biolog
latent
infect
cell
line
tcell
monocyt
use
rt
assay
whole
cell
extract
obtain
western
blot
uninfect
cem
jurkat
cell
line
tcell
uninfect
cell
line
monocyt
use
viabil
assay
whole
cell
extract
obtain
western
blot
uninfect
cell
grown
media
contain
fb
lglutamin
streptomycinpenicillin
qualiti
biolog
cell
incub
gener
gift
dr
mingdaw
tsai
institut
biolog
chemistri
academia
sinica
nankang
taipei
taiwan
eighteen
subject
serum
sampl
ltnp
hiv
infect
subject
receiv
haart
therapi
uninfect
individu
obtain
washington
dc
site
women
interag
hiv
studi
wih
tabl
wih
nih
multicent
studi
natur
histori
infect
women
ltnp
defin
wih
hiv
infect
diseas
free
least
five
year
count
greater
visit
histori
antiretrovir
therapi
serum
sampl
subject
deplet
abund
serum
protein
use
proteomelab
high
capac
spin
column
proteom
partit
kit
spin
column
consist
antihuman
serum
albumin
antiigg
antifibrinogen
antitransferrin
antiiga
antiigm
antihdl
antiapo
ai
antiapo
aii
antihaptoglobin
glycoprotein
conjug
polymer
microbead
twenti
microlit
serum
sampl
dilut
dilut
buffer
ran
spin
column
low
abund
protein
collect
flowthrough
subsequ
high
abund
bound
protein
retain
elut
low
ph
strip
buffer
protein
concentr
low
high
abund
fraction
calcul
pool
indic
prowlcgiprofoundex
databas
peptid
mass
fingerprint
analysi
fifti
microlit
pool
low
abund
ltnp
serum
sampl
individu
low
abund
ltnp
serum
sampl
incub
either
indic
volum
brought
tne
western
blot
perform
valid
protein
identifi
deplet
serum
sampl
whole
cell
extract
obtain
cell
cultur
pellet
wash
twice
ml
phosphat
buffer
salin
pb
qualiti
biolog
centrifug
cell
pellet
resuspend
lysi
buffer
mm
trishcl
ph
mm
nacl
mm
edta
mm
naf
mm
mm
dtt
one
complet
proteas
cocktail
ml
incub
ice
min
gentli
vortex
everi
min
cell
lysat
transfer
eppendorf
tube
centrifug
rpm
min
supernat
transfer
fresh
tube
protein
concentr
determin
use
biorad
protein
assay
biorad
hercul
ca
antibodi
pctair
rb
actin
purchas
santa
cruz
biotechnolog
santa
cruz
ca
antibodi
purchas
cell
signal
danver
cell
treat
gst
fascaplysin
nm
nm
supernat
collect
test
presenc
viru
hour
post
treatment
jurkat
treat
gst
hour
prior
infect
dual
tropic
strain
supernat
collect
variou
time
point
post
infect
test
presenc
viru
post
treatment
viral
supernat
incub
plate
revers
transcriptas
rt
reaction
mixtur
contain
rt
buffer
mm
trishcl
mm
dtt
mm
mgcl
mm
kcl
triton
poli
pd
ttp
mixtur
incub
overnight
reaction
mix
spot
deae
filtermat
paper
wash
four
time
na
hpo
three
time
water
dri
complet
rt
activ
measur
betapl
counter
wallac
gaithersburg
md
five
thousand
cell
plate
per
well
plate
next
day
cell
treat
gst
fascaplysin
nm
nm
fortyeight
hour
later
mtt
reagent
mgml
ad
well
plate
incub
hour
next
dmso
ad
well
solubil
violet
crystal
assay
read
nm
cell
wash
pb
fix
ethanol
follow
rehydr
pb
cell
stain
pb
contain
ugml
propidium
iodid
sigma
ugml
rnase
sigma
cell
analyz
bd
facscalibur
flow
cytomet
cell
cycl
analysi
measur
apoptosi
perform
use
cellquest
softwar
aggreg
debri
exclud
gate
paramet
apoptosi
consid
popul
cell
